But a note out of Macquarie suggests Ramsay is the best at “playing to its strengths” with its brownfield projects in large metropolitan areas capturing the broker’s attention.
Ramsay has a number of sites slated for possible expansion on Queensland’s Sunshine Coast, a more regional location for the company, but one with good exposure to older age groups.
Ramsay shares have been on a downward slide in the last 12 months, dropping from $70.42 at this time last year to an April 23 close of $62.70, but Macquarie’s view on Ramsay is positive, with the broker placing an outperform rating on the stock and a price target of $74.50.
Macquarie is more cautious of $3.53 billion market cap company Healthscope, with a neutral rating on the stock and a price target of $1.95.
Out of the hospital sphere CSL Limited (ASX: CSL) remains the most talked about health care stock on the ASX, with the company playing to the needs of the growing sector of biotherapeutics like a pro.
Outside of the healthcare space find OUR #1 dividend pick here
Financial year 2018 is here and The Motley Fool’s dividend detective Andrew Page has revealed his must buy dividend share to grow your wealth in 2018.
You might not know this market leader's name, but it's rapidly expanding into a highly profitable niche market here in Australia. Even better, the shares boast a strong, fully franked dividend that should balloon in the years to come. In other words, we're looking at the holy grail of incredible long-term growth potential AND income you can watch accruing in your account in real time!
Simply click here to grab your FREE copy of this up-to-the-minute research report on our #1 dividend share recommendation now.
Motley Fool contributor Carin Pickworth has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.